AASLD Notebook: Inventiva Eyes Second-To-Market Possibility In NASH

While much of the buzz at the 2023 American Association for the Study of Liver Disease conference was around Madrigal Pharmaceuticals, Inc. and the 14 March US Food and Drug Administration action date for resmetirom in non-alcoholic steatohepatitis, numerous NASH drug developers presented data at the meeting.

Two, Viking Therapeutics, Inc. and Terns Pharmaceuticals, Inc., are advancing their own THRβ agonists, the same drug class as resmetirom. However, while Viking is trying to balance its NASH ambitions with programs for obesity and rare disease, Terns is looking to optimize its combination regimens beyond what it has in-house right now